Friday, November 22, 2019 Daily Archives

Why Characterizing Protein Stability Matters For Drug Development

Characterizing a protein’s stability provides key insights into the expression, signaling, and regulatory roles of a molecule. This is necessary for numerous applications from understanding the molecular basis for certain diseases to ensuring more effective drug development. Ultimately, the stability of a protein is closely tied to its functional activity. Whether you’re just starting to learn about characterizing protein stability or you’re looking for a refresher, this guide has some helpful tips to answer why it’s important, what technologies are…

Liminal divesting Prometic Bioseparations to KKR in $100m deal

Investment firm KKR is set to acquire Prometic Bioseparations, the chromatography and bioprocessing business of Liminal BioSciences. Global biotech firm Liminal BioSciences, which changed its name in September from Prometic Life Sciences, has announced the sale of Prometic Bioseparations (PBL) to KKR. The investment firm will pay £45 million ($58 million), with up to £32 million ($42 million) more upon closing of the deal. PBL offers chromatography columns and services for the biomanufacturing industry. Its Evolve Process column range offers…

Thermogenesis cell preservation tech to drive CAR-T cancer trial eligibility

Rebranded Thermogenesis used its quarterly call to outline plan to target unmet tech and manufacturing needs in the CAR-T sector. The firm – known until November 1 as Cesca Therapeutics – will pitch its cell processing tools and its new services joint venture – Immunecyte – as a way to help reduce CAR-T manufacturing, storage and distribution costs. CEO Chris Xu told analysts on Thermogenesis’ third quarter call that Immunecyte – formed with Healthbanks Biotech last month – would be…